Patent · US Active

Method of endogenous stem cell activation for tendon/ligament osseointegration

US12232949B2 · kind B2 · utility

0Cited by

2References

14Claims

0Family size

Assignee

Cedars Sinai Medical Center · US

Inventors

Dan Gazit · Modiin-Maccabim-Reut, IL
Gadi Pelled · Los Angeles, US
Thomas Kremen · Dublin, US

Key dates

Filing date	Feb 28, 2017
Grant date	Feb 25, 2025
Priority date	—
Expiry date	Mar 9, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K14/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Tendon and ligament injuries are common in orthopaedic clinical practice and cause substantial morbidity in sports and in routine daily activities. While surgical reconstruction is effective, the majority of patients suffer from a prolonged period of recovery because of limited regeneration capacity of the tendon-bone interface. Here, the Inventors have established an approach for promoting tendon/ligament integration. By first recruiting endogenous stem cells to the site of injury, bone morphogenic proteins (BMPs), are then delivered in vivo to promote repair. Significant acceleration of healing via the above methods and compositions leads to fast recovery and return to normal activities, thereby providing new therapeutic avenues for treatment of injuries involving the tendon-bone interface.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.